GLP-1 Drugs Could Cut 14,400 U.S. Knee Replacements a Year, Study Finds
Updated
Updated · The Guardian · Jun 2
GLP-1 Drugs Could Cut 14,400 U.S. Knee Replacements a Year, Study Finds
3 articles · Updated · The Guardian · Jun 2
Three years of semaglutide or tirzepatide was linked to a nearly 5-percentage-point lower chance of knee replacement eight years after knee osteoarthritis diagnosis, according to a University of Maryland study.
The researchers analyzed 6.8 million adults with knee osteoarthritis, including matched cohorts of 42,000 GLP-1 users and 42,000 non-users, and found smaller risk reductions after one year of treatment.
If all eligible U.S. patients with knee arthritis and obesity or metabolic disease took those drugs for three years, the authors estimated up to 14,400 fewer knee replacements annually; the UK figure was more than 1,500.
The study points to weight loss plus possible anti-inflammatory and pain-relieving effects, but outside experts said it does not prove the drugs prevent surgery and warned they are not approved to treat osteoarthritis.
Will a future injection directly into the knee make both weight-loss drugs and arthritis surgery obsolete?
How are weight-loss drugs secretly reprogramming cartilage cells to fight arthritis, independent of shedding any pounds?
GLP-1 Receptor Agonists for Knee Osteoarthritis: Delaying Surgery, Improving Outcomes, and Navigating Long-Term Safety
Overview
Recent findings highlight a major shift in managing knee osteoarthritis, especially for people with obesity. GLP-1 receptor agonist drugs, which have become much more popular in the past decade, are now seen as a promising non-surgical way to delay or prevent knee replacement surgeries. This change follows FDA approvals for drugs like liraglutide and semaglutide, first for diabetes and then for obesity. Research shows that people with knee osteoarthritis who use weight loss medications are less likely to need knee replacements, emphasizing the strong link between weight management and joint health.